Suspension Cell Line Development for High-Titer Virus Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing viral vectors, such as lentivirus, in gene therapy and CAR-T cell therapy face challenges including reliance on fetal bovine serum (FBS), batch-to-batch variation, and difficulty in scaling up adherent cell technologies, which are time-consuming and inefficient, leading to low viral vector titers and high host cell protein (HCP) content.
Innovation Solution
A method for developing cell lines suitable for suspension cell culture, involving the generation and selection of cell clones with high transfection efficiency, adapted to grow in serum-free media, allowing for efficient virus production in bioreactors, thereby reducing production time and costs while minimizing HCP content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If adherent cell technology with FBS is used for virus production, then high lentivirus expression titer is achieved, but batch-to-batch variation occurs and scaling up is difficult
Solution Approach 1:
The patent changes the culture parameters from adherent to suspension culture mode, and from FBS-containing media to chemically defined serum-free media. This parameter transformation enables consistent batch-to-batch production while maintaining high virus titers and allowing scalable bioreactor production.
2Adaptability or versatility
If traditional suspension domestication of HEK293 cells is performed by gradually reducing serum concentration, then suspension culture capability is achieved, but the process takes 3-5 months and transfection efficiency remains low
Solution Approach 1:
The patent performs preliminary selection of cell clones with high transfection efficiency in adherent culture before suspending them. This preliminary action ensures that only cells with desirable characteristics are subjected to suspension domestication, dramatically reducing the time required (from 3-5 months to much shorter periods) while maintaining high transfection efficiency in the final suspension cell line.
Solution Approach 2:
The domestication process is segmented into distinct steps: (1) selection of high transfection efficiency clones in adherent culture, (2) suspension adaptation, and (3) verification of virus production capability. This segmentation allows systematic optimization at each stage rather than attempting simultaneous optimization of all parameters.
3Ease of manufacture
If HEK293 cells are used for virus production, then human embryonic kidney cell availability is ensured, but chromosome heterogeneity leads to slow growth rate and low transfection efficiency
Solution Approach 1:
The patent changes the selection parameters for cell clones, specifically selecting for high transfection efficiency and high virus production capability rather than relying on the inherent characteristics of HEK293 cells. This parameter change in clone selection overcomes the limitations of chromosome heterogeneity and enables high productivity in suspension culture.
Data Source
AI summary
A method for generating a cell line for producing virus in suspension cell culture. The method comprises generating a plurality of cell clones growing in adherent cell culture, identifying a group of cell clones with high transfection efficiency, generating a plurality of cell clones growing in suspension cell culture and identifying a cell clone suitable for producing virus in suspension cell culture. The method disclosed herein the method can shorten the domestication time from at least 1 month to 7-14 days, and the amount of medium used during the domestication process can also be greatly reduced, reducing production costs.